Novo Nordisk A/S (NYSE:NVO) Stock Price Down 2.2%

Novo Nordisk A/S (NYSE:NVO - Get Free Report)'s share price was down 2.2% during trading on Tuesday . The company traded as low as $124.57 and last traded at $124.64. Approximately 1,278,605 shares traded hands during trading, a decline of 75% from the average daily volume of 5,044,459 shares. The stock had previously closed at $127.46.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on NVO shares. Cantor Fitzgerald reiterated an "overweight" rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a research report on Monday, April 1st. Morgan Stanley assumed coverage on Novo Nordisk A/S in a research note on Tuesday, January 23rd. They issued an "overweight" rating and a $120.00 price objective on the stock. Finally, UBS Group assumed coverage on Novo Nordisk A/S in a research report on Tuesday, January 16th. They set a "neutral" rating on the stock. Two investment analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, Novo Nordisk A/S presently has an average rating of "Moderate Buy" and an average price target of $126.25.

Novo Nordisk A/S Stock Down 2.1 %

The firm has a 50-day moving average of $125.32 and a 200 day moving average of $109.16. The stock has a market capitalization of $560.22 billion, a price-to-earnings ratio of 46.15, a price-to-earnings-growth ratio of 2.10 and a beta of 0.41. The company has a current ratio of 0.82, a quick ratio of 0.64 and a debt-to-equity ratio of 0.19.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its quarterly earnings data on Wednesday, January 31st. The company reported $0.71 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.66 by $0.05. Novo Nordisk A/S had a return on equity of 90.36% and a net margin of 36.03%. The company had revenue of $9.51 billion for the quarter, compared to the consensus estimate of $9.14 billion. On average, sell-side analysts anticipate that Novo Nordisk A/S will post 3.32 earnings per share for the current year.

Novo Nordisk A/S Increases Dividend

The firm also recently disclosed a Semi-Annual dividend, which was paid on Tuesday, April 2nd. Shareholders of record on Monday, March 25th were issued a dividend of $0.664 per share. The ex-dividend date of this dividend was Friday, March 22nd. This is an increase from Novo Nordisk A/S's previous Semi-Annual dividend of $0.22. This represents a yield of 0.9%. Novo Nordisk A/S's payout ratio is currently 49.17%.

Institutional Investors Weigh In On Novo Nordisk A/S

Institutional investors have recently made changes to their positions in the company. IHT Wealth Management LLC lifted its holdings in shares of Novo Nordisk A/S by 3.5% during the fourth quarter. IHT Wealth Management LLC now owns 2,369 shares of the company's stock valued at $321,000 after purchasing an additional 80 shares during the last quarter. Cravens & Co Advisors LLC lifted its holdings in shares of Novo Nordisk A/S by 1.0% during the first quarter. Cravens & Co Advisors LLC now owns 8,250 shares of the company's stock valued at $1,059,000 after purchasing an additional 85 shares during the last quarter. U.S. Capital Wealth Advisors LLC lifted its holdings in shares of Novo Nordisk A/S by 0.6% during the fourth quarter. U.S. Capital Wealth Advisors LLC now owns 15,421 shares of the company's stock valued at $1,595,000 after purchasing an additional 90 shares during the last quarter. Hancock Whitney Corp lifted its holdings in shares of Novo Nordisk A/S by 4.1% during the first quarter. Hancock Whitney Corp now owns 2,342 shares of the company's stock valued at $373,000 after purchasing an additional 92 shares during the last quarter. Finally, SRS Capital Advisors Inc. lifted its holdings in shares of Novo Nordisk A/S by 9.6% during the first quarter. SRS Capital Advisors Inc. now owns 1,060 shares of the company's stock valued at $169,000 after purchasing an additional 93 shares during the last quarter. 11.54% of the stock is currently owned by institutional investors.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.